Survival rate

Honoring three dreamers: Entrepreneur, artist, civic leader to receive top accolades at St. Jude Spirit of the Dream

Retrieved on: 
火曜日, 5月 7, 2024
Philanthropy, Oncology, Consumer, Continuing, Hospitals, University, Fund Raising, Education, Foundation, Children, Other Philanthropy, Health, Sickle cell disease, African Americans, National Cancer Institute, Business, Alpha Phi Alpha, Food, Commerce, National Medical Association, African, Greater Memphis Chamber, NCI-designated Cancer Center, Chamber of commerce, Love, Life, Coors Brewing Company, Child, Dream, Delta, Family, Executive, Hospital, ALSAC, Travel, Housing, Book, Research, Employment, Multimedia, Organization, Society, Cancer, Hope, Federal Reserve Bank, Survival rate, Writing, The J.M. Smucker Company, Legacy Award, Honeywell, Nursing

The annual St. Jude Spirit of the Dream presented by W&T Contracting Corporation announced today the recipients of its two highest accolades: the Legacy Award and the St. Jude Spirit of the Dream award.

Key Points: 
  • The annual St. Jude Spirit of the Dream presented by W&T Contracting Corporation announced today the recipients of its two highest accolades: the Legacy Award and the St. Jude Spirit of the Dream award.
  • Honors a person or institution embodying the lifesaving mission of St. Jude Children’s Research Hospital and its founder Danny Thomas.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on X , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Miami's Philanthropic Community Raises $785,000 for St. Jude Children's Research Hospital at 22nd Annual FedEx/St. Jude Angels & Stars Gala

Retrieved on: 
月曜日, 5月 6, 2024
Online, Other Consumer, Celebrity, Oncology, Philanthropy, TV and Radio, Hospitals, Music, Children, Hispanic, Fund Raising, Foundation, Family, Entertainment, Consumer, Health, InterContinental, Cancer, Radio, Hope, Hospital, Travel, Housing, NCI-designated Cancer Center, Survival rate, Love, National Cancer Institute, Human, Television, Food, Carnival Cruise Line, Child, Multimedia, FedEx, Nightclub

The annual gala, now in its 22nd year, unites members of the South Florida community to support the mission of St. Jude Children's Research Hospital® : Finding cures.

Key Points: 
  • The annual gala, now in its 22nd year, unites members of the South Florida community to support the mission of St. Jude Children's Research Hospital® : Finding cures.
  • Since its inception, the gala has raised more than $20 million for the lifesaving work of St. Jude.
  • View the full release here: https://www.businesswire.com/news/home/20240506835733/en/
    This Saturday South Florida’s philanthropic community celebrated the 22nd Annual Fed/Ex St. Jude Angels and Stars Gala, which raised $785,000 for the children of St. Jude Children’s Research Hospital.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on X, Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC

Retrieved on: 
月曜日, 5月 6, 2024
Oncology, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Safety, Food, American Urological Association, Survival rate, Grady Memorial Hospital, Month, Recurrence, Carcinoma in situ, Nadofaragene firadenovec, BCG, Disease, CIS, Patient, Ferring Pharmaceuticals, NMIBC, AUA, Assistant, Annual general meeting, Journal, Pharmaceutical industry

Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.

Key Points: 
  • Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.
  • These data, which are the longest follow-up of efficacy and safety data reported for a novel agent for BCG-unresponsive NMIBC, were simultaneously published ahead of print and will be included in the July issue of The Journal of Urology®.
  • ADSTILADRIN is the first and only intravesical non-replicating adenoviral vector-based gene therapy approved by the U.S. Food and Drug Administration (FDA) in patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors.
  • The mechanism of action of ADSTILADRIN is designed to deliver the human interferon-alfa 2b gene (IFNα2b) directly into the bladder to enable secretion of interferon alfa-2b protein with a single treatment every three months.

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

Retrieved on: 
日曜日, 5月 5, 2024
UTI, Congress, FDA, FGFR, Cancer, Urinary diversion, Pyelonephritis, Erdafitinib, Hospital, Safety, Food, American Urological Association, Survival rate, FGFR3, Johnson & Johnson, Recurrence, Abstract, Cohort, BCG, PD-1, PD-L1, Disease, Bladder cancer, Patient, Medicine, AUA, Urinary bladder, MUC, Face, SAN, Sepsis, EAU, Pharmaceutical industry

SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. These data were featured today in an Oral Presentation Session (Abstract # PD48-02) at the 2024 American Urological Association (AUA) Annual Meeting taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • First results were featured at the European Society for Medical Oncology 2023 Congress, with interim results presented at the European Association of Urology (EAU) 2024 Annual Congress.
  • "Results presented today further underscore that TAR-210 for the localized treatment of bladder cancer may offer a promising alternative for patients with limited treatment options."
  • At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the 2 cohorts.
  • Of the 21 patients in C1 with HR-NMIBC, the 12-month recurrence-free (RF) survival rate was 90%.

PANCAN PURPLESTRIDE UNITED CELEBRITIES, SURVIVORS, CAREGIVERS AND SUPPORTERS NATIONWIDE AT THE ULTIMATE WALK TO END PANCREATIC CANCER

Retrieved on: 
月曜日, 4月 29, 2024
Family, Cancer, Pancreatic cancer, City, Survival rate, Research, Survivor, Disease, Federation, JD, Patient, Pancreatic Cancer Action Network, LOS, MBA, Prairie, Star Trek, Little House, Pharmaceutical industry

LOS ANGELES, April 29, 2024 /PRNewswire/ -- This past Saturday, April 27, the Pancreatic Cancer Action Network (PanCAN) held its largest annual fundraiser, PanCAN PurpleStride®, the ultimate walk to end pancreatic cancer. For the third year in a row, PurpleStride took place nationwide across nearly 60 cities as survivors, supporters, celebrities and special guests walked in solidarity to raise awareness and much-needed funds for pancreatic cancer, one of the world's deadliest forms of cancer. It is the number one way PanCAN raises funds to fuel its mission and the dollars raised change the lives of people facing pancreatic cancer and advance progress against the disease. Nearly 70,000 people were expected to attend across the country with a goal of raising $19 million towards fighting the disease.

Key Points: 
  • Pancreatic cancer is the third leading cause of cancer-related death in the United States with a five-year survival rate of just 13%.
  • Coast to coast, the pancreatic cancer community came together to raise awareness and funding for this disease.
  • At PurpleStride D.C., actor Rosario Dawson walked in honor of her father who is currently battling pancreatic cancer.
  • For more information on the Pancreatic Cancer Action Network and its urgent mission to save lives, visit pancan.org or follow PanCAN on Twitter , Instagram and Facebook .

Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

Retrieved on: 
月曜日, 4月 29, 2024
Stent, FDA, Leg, Education, Physician, Knee, Esprit, TCT, Everolimus, Food, PAD, Survival rate, Breast, Columbia University, Conference, Foot, Disease, Amputation, Oxygen, Standard of care, Artery, Plaque, Peripheral artery disease, BTK, CLTI, Pharmaceutical industry

The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.

Key Points: 
  • The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
  • Until today, there were no stents or drug-coated balloons approved for use below the knee in the U.S.
  • The Esprit BTK System is a first-of-its-kind dissolvable stent and is comprised of material similar to dissolving sutures.
  • That's why we're revolutionizing treatments with resorbable scaffold technology below the knee," said Julie Tyler, senior vice president of Abbott's vascular business.

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
水曜日, 4月 17, 2024
Mortality, FDA, Nephrology, Risk, Nephron, Partnership, Hepatorenal syndrome, Acute kidney injury, ICU, White, AKI, Chronic kidney disease, Monocyte, Heart failure, SCD, Dialysis, CRRT, CKRT, KRT, Inflammation, Safety, Insurance, Clinical study design, Therapy, Clinical trial, G&A, Sepsis, University, HDE, Survival rate, Neutrophil, Acute respiratory distress syndrome, Patent, Cardiorenal syndrome, European Journal, Physician, Manuscript, Bank statement, Standard of care, Pharmaceutical industry

DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
  • “Lastly, I’m pleased that we have filed our Form 10-K for 2023, which includes restated 2022 financial statements,” said Mr. Schlorff.
  • Mr. Green brings to SeaStar Medical extensive financial experience at public medical device and therapeutics companies.
  • The Company reported cash of $176,000 as of December 31, 2023, compared with $47,000 as of December 31, 2022.

Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma

Retrieved on: 
水曜日, 4月 17, 2024
Society, Nature, SNO, Nivolumab, Service provider, Survival rate, Immunotherapy, Standard of care, Bevacizumab, Glioblastoma, Immune tolerance, Weapon, Patient, Peptide, Inflammation, Immune system, Neoplasm, Vaccine

PARIS, April 17, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with recurrent glioblastoma (EOGBM1-18/ROSALIE trial).

Key Points: 
  • A total of 100 patients have been enrolled in ROSALIE, an international, open-label Phase 1/2 trial of EO2401 an innovative, off-the-shelf immunotherapy derived from Enterome’s oncomimicry platform.
  • Jan Fagerberg, Chief Medical Officer of Enterome, said: “The achievement of the first trial evaluating EO2401 represents a major milestone for Enterome.
  • The ROSALIE study represents the first demonstration of OncoMimics™ immunotherapies’ ability to overcome immune tolerance, promising new avenues for targeting cancer cells.
  • I also would like to thank patients, their families, and investigators whose dedication made this groundbreaking study possible."

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Retrieved on: 
木曜日, 4月 11, 2024
FDA, Chemoradiotherapy, Food, Pancreatic cancer, SOC, Survival, Survival rate, MD, Tumor microenvironment, Doctor of Philosophy, PDAC, CADL, Cancer, Patient, Pancreatitis, Neoplasm, Standard of care, Therapy, Injection, Lung cancer, Pharmaceutical industry

NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.

Key Points: 
  • NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
  • “We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer.”
    “Obtaining Orphan Drug Designation marks a significant milestone for Candel, as we continue to develop CAN-2409 for pancreatic cancer,” said Garrett Nichols.
  • “We are excited by this FDA designation, which further supports Candel’s efforts in the development of medicines to cure less prevalent yet challenging to treat cancers.
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Uforia unites artists, communities nationwide to support St. Jude Children’s Research Hospital this Dia del Niño

Retrieved on: 
木曜日, 4月 25, 2024
TV and Radio, Music, Fund Raising, Foundation, Philanthropy, Family, Celebrity, Consumer, Entertainment, Health, Continuing, University, Education, Other Consumer, Parenting, Children, Oncology, Cancer, Radio, Hope, Hospital, Travel, Housing, NCI-designated Cancer Center, Survival rate, Love, National Cancer Institute, Uforia Audio Network, Research, Life, Food, Movement, Multimedia, Child, Angel

This Friday, musical artists Ana Bárbara and DannyLux will join the Uforia Audio Network to celebrate Dia del Niño by rallying audiences behind the lifesaving mission of St. Jude Children’s Research Hospital® : Finding cures.

Key Points: 
  • This Friday, musical artists Ana Bárbara and DannyLux will join the Uforia Audio Network to celebrate Dia del Niño by rallying audiences behind the lifesaving mission of St. Jude Children’s Research Hospital® : Finding cures.
  • Support from listeners, partners like Uforia and Ángeles de Esperanza enables St. Jude to help children everywhere by advancing research and treatment of childhood cancer and other life-threatening diseases.
  • St. Jude Children’s Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on X, Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.